On 7 June 1965, in Griswold v. Connecticut, the United States Supreme Court decided, in a seven to two decision, that married couples have the right to purchase and use contraceptives without government restriction. The case considered the constitutionality of a Connecticut state statute from 1879 that prohibited the sale or use of any contraceptive device or medication. In 1961, Estelle Griswold, an executive director of the Planned Parenthood League of Connecticut, hereafter PPLC, and physician Charles Lee Buxton were convicted for selling contraceptives at a pregnancy clinic they opened in New Haven, Connecticut, in violation of state law. Griswold and Buxton challenged the constitutionality of the Connecticut law, claiming it violated the Due Process Clause of the Fourteenth Amendment of the US Constitution, which states that the state government cannot infringe upon rights of citizens without a fair process, such as a trial. Griswold v. Connecticut helped establish an inferred right to privacy within the amendments of the US constitution, granting the right of married couples to access contraceptives and setting the foundation for future cases involving contraception, abortion, anti-sodomy laws, and marriage.

For women with polyendocrine metabolic ovarian syndrome, or PMOS, combination oral contraceptives are a first-line treatment. PMOS is a reproductive hormonal disorder that affects roughly one in ten women of reproductive age and causes symptoms such as an irregular menstrual cycle and hyperandrogenism, or an excess of male-typical hormones called androgens. Combination oral contraceptives are medications containing a mix of synthetic female hormones that women often use as a means of birth control. In the 1970s, researchers found that the synthetic female hormones in combination oral contraceptives can reduce excess androgens in women experiencing PMOS. Several medical conferences in the 1990s and early 2000s created a diagnostic standard for PMOS, which led to an increase in diagnoses across the world and expanded the number of women who were receiving combined oral contraceptives for PMOS management. By relieving hyperandrogenism, combination oral contraceptives help women manage the symptoms of PMOS and reduce their risk of long-term health problems.